Enzo Biochem IncNYSE:ENZ
- LAST PRICE1.0600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.0600/ 7
- Ask / Lots1.0700/ 2
- Open / Previous Close1.0400 / 1.0600
- Day Range
- 52 Week Range
- Volume1,949
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENZ |
|---|---|---|
| 09:32 ET | 1399 | 1.04 |
| 09:34 ET | 500 | 1.06 |
| 09:36 ET | 590 | 1.06 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Enzo Biochem Inc | 54.3M | -2.3x | --- |
Aclaris Therapeutics Inc | 83.0M | -0.9x | --- |
Aadi Bioscience Inc | 43.7M | -0.7x | --- |
Elutia Inc | 70.2M | -1.3x | --- |
Prenetics Global Ltd | 58.5M | -1.1x | --- |
Exicure Inc | 4.5M | 0.4x | --- |
Company Information
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.
Contact Information
- Headquarters
- 60 EXECUTIVE BLVDFARMINGDALE, NY, United States 11735
- Phone
- 516-755-5500
- Fax
- ---
Executives
- Chairman of the Board
- Steven Pully
- Chief Executive Officer, Chief Operating Officer
- Kara Cannon
- Chief Financial Officer
- Patricia Eckert
- General Counsel, Secretary
- Matthew Kupferberg
- Director
- Elazar Rabbani
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.3M |
|---|---|
Revenue (TTM) | $32.8M |
Shares Outstanding | 51.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-0.47 |
Book Value | $1.57 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -70.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
